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Introduction: Extra-pulmonary complications of Burkholderia cepacia complex (Bcc) infection in patients with cystic fibrosis are unusual. To the
best of the authors' knowledge no case of pyomyositis secondary to Bcc infection has been reported previously.
Case presentation: We report a case of pyomyositis of the forearm caused by Bcc infection in a patient with CF. We also briefly discuss the
management of pyomyositis.
Conclusion: Pyomyositis is a potential extra-pulmonary complication of Bcc infection in patients with CF. A high index of clinical suspicion is
required to make a prompt diagnosis. Final diagnosis may need MRI. An early diagnosis, aggressive medical therapy, multidisciplinary care and
timely surgical intervention are all essential for proper management of this condition.
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Infection with Burkholderia cepacia complex (Bcc) is
associated with significant increase in morbidity and mortality
[1–6]. Although a small number of cases of abscess formation
have been described in at-risk groups extra-pulmonary
manifestations are unusual [7–13]. We report a case of acute
Bcc pyomyositis.2. Case history
A 29 year old man with Cystic Fibrosis (CF) was admitted to
the ward with a four week history of pain and swelling in his leftAbbreviations: Bcc, Burkholderia cepacia complex; CF, Cystic Fibrosis;
CFRD, Cystic Fibrosis Related Diabetes.
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doi:10.1016/j.jcf.2009.04.007wrist and lower forearm. There was no history of trauma or
previous joint disease.
The diagnosis of CF had been made at the age of eight months
following presentationwith failure to thrive. Hewas homozygous
for the p.Phe508del mutation and pancreatic insufficient.
Complicating factors included CF related diabetes mellitus
(CFRD), low bone mineral density [lumbar spine L2–L4 z-score
–1.9] and chronic Burkholderia cenocepacia IIIa infection from
14 years of age. The identity of the Bcc isolate had been
confirmed previously by the reference laboratory at the Centre for
Infection, Colindale, London, UK. This isolate had been pan-
resistant to all tested antibiotics for several years, except to
minocycline. The patient was also ‘Intermittent’ for Pseudomo-
nas aeruginosa by Leeds criteria.
His lung function had remained stable with an FEV1 around
40% predicted. However, following a severe respiratory exacer-
bation at 27 years of age his FEV1 had fallen to 20% predicted
without subsequent recovery. Despite intensification of treatment,
including maintenance low dose oral corticosteroids and
continuous intravenous antibiotic administration, his clinicald by Elsevier B.V. All rights reserved.
Fig. 2. Coronal and axial sections of MRI showing the abscess within the distal/
mid forearm.
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dependent, and required escalating palliation for symptom
control.
At admission his left wrist and forearm were red, swollen
and warm to touch (Fig. 1). There was acute tenderness and
reduced range of movement at the wrist joint but no effusion,
rash or skin break. No other joints were affected. He was
generally unwell, cachectic (BMI 16.1), dyspnoeic at rest on
28% oxygen therapy (10 L/min), but apyrexial. The
differential diagnosis included septic arthritis, fracture, gout,
cellulitis and venous thrombosis. After initial assessment, he
was commenced on adequate pain relief and continued on
intravenous antibiotics, (tobramycin, meropenem) plus oral
minocycline, the only agent to which the isolate had recently
been susceptible in vitro.
Initial investigations showed serum C-reactive protein (CRP)
143 mg/L (normal rangeb5 mg/L), (but this had been chronically
elevated at around 120 mg/L for the past six months), serum urate
level (197 mmol/L) and total white blood cell count 38×109/L
(neutrophils 37.2×109/L). A small periosteal reaction at the head
of the radius was seen on the plain radiograph. There was no
evidence of fracture or hypertrophic pulmonary osteoarthropathy
(HPOA). Ultrasound of the left arm showed no evidence of deep
vein thrombosis. Magnetic resonance imaging (MRI) scan
showed a loculated collection within the mid/distal forearm
measuring 7×3.5×2 cm, consistent with an abscess and
extending to the interosseous membrane (Fig. 2). The underlying
bone, wrist and elbow joints were normal.
Initial ultrasound-guided aspiration was unsuccessful as the
collection was extremely loculated. Open drainage performed
under axillary nerve block exposed a large abscess extending
through the interosseous membrane to deep and superficial
flexors. Evacuation, curettage and debridement of necrotic
muscles were performed with subsequent clinical resolution of
the abscess. B. cenocepacia IIIA infection was confirmed from
sputum and pus isolates by molecular methods at a reference
laboratory (Centre for Infection, Colindale, London, UK). Both
isolates were pan-resistant, including to minocycline. The
isolates were also positive for cable pili. In-house PFGE showed
both isolates clustered with isolates from the ET12 lineage.Fig. 1. Showing redness and swelling of the distal part of the left forearm.Intravenous antibiotics were continued to control pulmonary
infection.
3. Discussion
The Bcc comprises a group of closely related species, some
of which have emerged as life-threatening pulmonary patho-
gens. Bcc infection in patients with CF may have little or no
impact on lung function, provoke a more rapid deterioration or,
result in a fulminant deterioration associated with bacteraemia
and referred to as the “cepacia syndrome”. B. cenocepacia,
especially the ET12 lineage, is a particularly virulent clone
which has spread across North America and Europe through
patient to patient transmission. It is unusual for Bcc to
metastasise away from the lungs but extra-pulmonary sites of
infection in non-CF individuals have included the endocardium,
peritoneum, wounds, urogenital tract, bones, joints and central
nervous system [6]. There have been reports of Bcc related
abscesses in the spleen, liver, brain, skin, spinal cord, bladder
wall and lung [7–12]. A Bcc chest wall abscess in a person with
CF has been described [13]. To our knowledge this is the first
report of peripheral B. cenocepacia pyomyositis in CF. Our
patient may have been predisposed to metastatic spread due to
underlying CFRD and corticosteroid therapy.
The B. cenocepacia IIIA isolate in this case was resistant to all
tested antimicrobials. It is unit policy to treat all B. cenocepacia
infections with a combination of three agents. The decision to use
tobramycin, meropenem andminocycline was primarily based on
the fact thatmeropenem andminocycline are often themost active
agents against B. cenocepacia in vitro. Synergy studies were not
undertaken as there is no evidence as yet that they help improve
clinical outcomes. Minocycline and meropenem are known to
enter muscle. The penetration of tobramycin into muscle is
unknown but not thought to be good. It is our policy to consider
long term intravenous antibiotics in patients with aggressive
pulmonary infection and clinical deterioration. Such therapy can
stabilise individuals and has proved successful in controlling
symptoms and as a bridge to lung transplantation.
Infectious myositis, an acute infection of skeletal muscle, is
increasing in prevalence, particularly in association with HIV
disease [14]. It may be caused by viral, bacterial, fungal, or
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myalgias and/or myositis. Bacterial and fungal infections are
more common among immunocompromised patients and
usually cause a local myositis which may be associated with
sites compromised by trauma or surgery. Localised collections
within the muscles are referred to as pyomyositis. Other
pyogenic causes of myositis include gas gangrene, Streptococ-
cal group A myonecrosis, and other types of non-clostridial
myonecrosis. Early recognition and treatment are necessary as
myositis may rapidly become life-threatening [15].
The typical presentation is an asymmetric swelling of an
isolated muscle, with exquisite pain and fever. Magnetic
resonance imaging of the affected area suggests the diagnosis.
There are many potential pathogens and therefore muscle
biopsy and direct identification of the pathogen on tissue culture
are required [14]. The differential diagnosis includes arthritis,
whether inflammatory or septic, and extra capsular infections
such as pyomyositis and osteomyelitis.
This case report represents a rare but important complication
associated with Bcc infection in people with CF. Its incidence
may increase with improved survival and the use of long term
antibiotic therapy.
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